Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
On 9/21/09, Provectus Pharma (OTC: PVCT.OB) ($0.96, +1%, above-average volume on 21-Sep) announced that it completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. The primary objective of the Phase 2 study is to investigate the effectiveness of intralesional (IL) PV-10[More...]
Provectus Pharmaceuticals, Inc.
(Public, OTC:PVCT)
StocksHaven Investments profiles one of the most exciting up-and-coming anti-cancer companies in the industry, Provectus Pharmaceuticals (OTC:PVCT).[More...]
Craig Dees, CEO of Provectus Pharmaceutical, Inc. (OTC BB: PVCT), talks exclusively with the MN1 news team about his company and its goals. Provectus Pharmaceutical is actively engaged in the design and development of pharmaceutical technologies for the treatment of metastatic melanoma, breast cancer, and liver cancer.
Get daily news and insights for the advertising, automotive, energy, financial services, food, health care, media, pharmaceutical, retail, technology, and travel industries.
